PRLD
USDPrelude Therapeutics Incorporated Common Stock
Echtzeitkurs
Kursdiagramm
Schlüsselkennzahlen
Marktkennzahlen
Eröffnung
$1.190
Hoch
$1.280
Tief
$1.173
Volumen
1.13M
Unternehmensfundamentaldaten
Marktkapitalisierung
71.5M
Branche
Biotechnologie
Land
United States
Handelsstatistiken
Durchschnittliches Volumen
1.27M
Börse
NMS
Währung
USD
52-Wochen-Spanne
Ähnliche Nachrichten
Prelude Therapeutics Announces Exclusive Option Agreement with Incyte to Advance Mutant Selective JAK2V617F JH2 Inhibitors
Incyte secures an exclusive option to acquire Prelude's mutant selective JAK2V617F JH2 inhibitor program Mutant selective JAK2V617F JH2 inhibitors have disease-modifying potential in treating patients living with
Prelude Therapeutics Announces Strategic Business Update
Prelude to prioritize development of mutant selective JAK2V617F JH2 inhibitor and KAT6A selective degrader programs Pausing further clinical development of SMARCA2 selective degrader programs JAK2V617F option agreement
Prelude Therapeutics Announces Publication of Abstracts for Presentation at the American Society of Hematology 67th Annual Meeting
WILMINGTON, Del., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (NASDAQ:PRLD) ("Prelude" or the "Company"), a clinical-stage precision oncology company, today announced the publication of two
Ähnliche Aktien
AGNCO
AGNC Investment Corp. Depositary Shares each representing a 1/1000th interest in a share of 6.50% Series E Fixed-to-Floating Cumulative Redeemable Preferred Stock
PTIX
Protagenic Therapeutics Inc.
BBW
Build-A-Bear Workshop Inc.
BGSF
BGSF Inc.
BMEZ
BlackRock Health Sciences Term Trust Common Shares of Beneficial Interest
Bleiben Sie auf dem Laufenden
Preisalarme setzen, KI-Analyse-Updates und Echtzeit-Marktnachrichten erhalten.